Adocia's shares are suspended from trading on the Paris Bourse on Thursday, pending the release of a press release, the biotech company announced.

As a reminder, the financial situation of the company, which specializes in the treatment of diabetes and obesity, had appeared critical for several months.

At March 31, its cash position stood at 13.9 million euros, giving it financial visibility until September 2023, while its net financial debt amounted to 21.5 million euros.

The biotech had recently acknowledged that its cash situation no longer enabled it to meet its commitments to its lenders, prompting it to enter into negotiations with them.

Adocia had warned that, in the absence of strategic solutions and an agreement with its creditors, its cash horizon would be reduced to the end of June 2023.

Copyright (c) 2023 CercleFinance.com. All rights reserved.